Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

IL-23 secreted by myeloid cells drives castration-resistant prostate cancer

Open access

Abstract

Patients with prostate cancer frequently show resistance to androgen-deprivation therapy, a condition known as castration-resistant prostate cancer (CRPC). Acquiring a better understanding of the mechanisms that control the development of CRPC remains an unmet clinical need. The well-established dependency of cancer cells on the tumour microenvironment indicates that the microenvironment might control the emergence of CRPC. Here we identify IL-23 produced by myeloid-derived suppressor cells (MDSCs) as a driver of CRPC in mice and patients with CRPC. Mechanistically, IL-23 secreted by MDSCs can activate the androgen receptor pathway in prostate tumour cells, promoting cell survival and proliferation in androgen-deprived conditions. Intra-tumour MDSC infiltration and IL-23 concentration are increased in blood and tumour samples from patients with CRPC. Antibody-mediated inactivation of IL-23 restored sensitivity to androgen-deprivation therapy in mice. Taken together, these results reveal that MDSCs promote CRPC by acting in a non-cell autonomous manner. Treatments that block IL-23 can oppose MDSC-mediated resistance to castration in prostate cancer and synergize with standard therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-018-0266-0

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 423

Metadata

Authors
Calcinotto, A., Spataro, C., Zagato, E., Di Mitri, D., Gil, V., Crespo, M., De Bernardis, G., Losa, M., Mirenda, M., Pasquini, E., Rinaldi, A., Sumanasuriya, S., Lambros, M. B., Neeb, A., Lucianò, R., Bravi, C. A., Nava-Rodrigues, D., Dolling, D., Prayer-Galetti, T., Ferreira, A., Briganti, A., Esposito, A., Barry, S., Yuan, W., Sharp, A., de Bono, J., & Alimonti, A.
Affiliations
  • Institute of Oncology Research (CH)
  • Royal Marsden NHS Foundation Trust (GB)
  • IRCCS Ospedale San Raffaele (IT)
  • AstraZeneca (United Kingdom) (GB)
  • University of Padua (IT)
Corresponding author
Alimonti, Andrea
Venue
Nature
Published
2018-06-27
Volume
559
Issue
7714
Pages
363-369
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2811252608
Cited by
394
References
45
Citations by year
2026: 42 · 2025: 35 · 2024: 52 · 2023: 55 · 2022: 55 · 2021: 58 · 2020: 47 · 2019: 34 · 2018: 15
FWCI
28.98
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion)
Funders
  • National Institute for Health and Care Research (CL-2014-22-001)
  • Academy of Medical Sciences (SGL014\1015)
  • Prostate Cancer UK (RIA15-ST2-018)
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (176045, 310030)
  • Nature
  • Medical Research Council (MR/M018318/1)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Keywords
castration-resistant prostate cancer, IL-23, myeloid-derived suppressor cells, androgen deprivation therapy resistance, androgen receptor, tumor microenvironment
MeSH terms
Myeloid-Derived Suppressor Cells, Androgens, Animals, Benzamides, Cell Survival, Humans, Male, Nitriles, Phenylthiohydantoin, Receptors, Androgen, Signal Transduction, Receptors, Interleukin, Cell Proliferation, Mice, Interleukin-23, Nuclear Receptor Subfamily 1, Group F, Member 3, Androgen Receptor Antagonists, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. https://app.cochat.ai/papers/10.1038/s41586-018-0266-0
The paper
Calcinotto, A., Spataro, C., Zagato, E., Di Mitri, D., Gil, V., Crespo, M., De Bernardis, G., Losa, M., Mirenda, M., Pasquini, E., Rinaldi, A., Sumanasuriya, S., Lambros, M. B., Neeb, A., Lucianò, R., Bravi, C. A., Nava-Rodrigues, D., Dolling, D., Prayer-Galetti, T., . . . Alimonti, A. (2018). IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. https://doi.org/10.1038/s41586-018-0266-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.